Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSCI / HK Connect June 2026 Implementation: Post-Announcement Positioning

HSCI / HK Connect June 2026: Pre-Implementation Update

HSCI / HK Connect June 2026 Implementation: Post-Implementation Review

HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

HSCI / HK Connect (March 2026): Implementation Today & Positioning

HSCI / HK Connect Inclusion (Mar 2026): Lessons from a Sep 2025 Retrospective Event Study

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>We screen the HSCI eligible universe for Q1 fast-entry candidates ahead of the May 2026 review.</li>
<li>Five stocks qualify as ADD candidates for HSCI inclusion this cycle. Fast entry rules apply.</li>
<li>The sixth name is mid-conviction, contingent on the committee's read of its specialist listing status.</li>
</ul>


We screen the HSCI eligible universe for Q1 fast-entry candidates ahead of the May 2026 review.
Five stocks qualify as ADD candidates for HSCI inclusion this cycle. Fast entry rules apply.
The sixth name is mid-conviction, contingent on the committee's read of its specialist listing status.


Beijing Haizhi Technology Group (2706 HK)

HSCI / HK Connect May 2026 Review Forecast

MiniMax

HSCI / HK Connect May 2026 Review Forecast